ICD10BillableValid for clinical use

ICD-10 Code E88.14: HIV-associated lipodystrophy

E88.14 is a billable ICD-10 diagnosis code used to classify HIV-associated lipodystrophy in medical records and claims. You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records. ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

What is this code?

ICD-10 codes are diagnosis classification codes used in healthcare records, reporting, coding workflows, and billing support. This code sits within the broader ICD-10 area for Endocrine, nutritional and metabolic diseases (E00-E89).

šŸ“‹Clinical overview

This entry records HIV-associated lipodystrophy. It does not identify a single cause, a particular HIV medicine, an affected body region or a laboratory result. The NIH educational source describes changes in fat distribution in HIV-associated contexts and emphasizes discussion with the treating team rather than independently stopping HIV treatment. The original HIV code-first instruction and conditional adverse-effect wording remain alongside this explanation. Neither those notes nor the related facial-filler services establish a personal drug reaction, cosmetic indication, medicine change or treatment eligibility.

When is it used?

  • May be used when a clinician documents hiv-associated lipodystrophy in a patient's medical record.
  • May appear in hospital records, claims, referrals, and clinical documentation.
  • This code can be used as a clinically usable diagnosis entry in standardized coding workflows.

What it does not mean

  • A code alone does not explain severity, treatment plan, or outcome.
  • A medical code should not be treated as a substitute for a doctor's diagnosis or advice.

🩺Clinical context

When commonly used
  • HIV-associated is the context named by this classification; it is not a statement that every listed medicine caused the condition or that every person has the same pattern of fat loss or accumulation. The title cannot establish a current treatment regimen, facial involvement, sex-related pattern, timing or degree of change. Ask which findings and history the responsible clinician documented. The association should not be inferred on the unspecified, partial, generalized or localized sibling pages merely because they share a classification branch or a billing link.
  • The NIH fact sheet explains that lipodystrophy can involve fat redistribution in people with HIV and that both HIV and some medicines may be relevant. It also discusses possible metabolic concerns. That background does not diagnose a high cholesterol level, insulin resistance or another condition in a reader. The person's actual pattern and clinical account matter. The source's examples are not a universal explanation of cause, and the code is not evidence that an individual takes any particular antiretroviral medicine.
  • The literal local code-first note is any human immunodeficiency virus [HIV] disease (B20). The additional-code note says code for adverse effect, if applicable, to identify drug (T37.5X5-). The words if applicable must not be removed: a drug adverse effect is not automatically established. The displayed T37.5X5- stem is not a complete final encounter code. Both notes retain their stored roles and order, while the responsible clinical and coding teams interpret the actual documentation; this page does not assign a drug cause or final code combination.
  • The original E88.1 parent and neighboring entries provide classification navigation, not a collection of extra conditions. Six SNOMED relationships belong to the parent, with their original directions, source snapshot and additional-code or external-cause qualifiers. They do not establish an AKT2- or CIDEC-related disorder, a laminopathy, an acquired cause or a congenital condition on this leaf. Shared chapter excerpts concerning diabetes, pregnancy or obesity also do not diagnose those conditions in a reader. Keep navigation, qualified associations and the personal clinical account distinct.
Common workup
  • Discuss the actual changes, relevant treatment history and the clinician's explanation of the HIV-associated context. A source example cannot tell where changes occurred in the reader or establish that their current medicine caused them. Ask what is known, what remains uncertain and which existing reports are relevant. The code does not provide an examination finding, a current HIV-treatment regimen, a metabolic result or evidence of a treatment failure. It also cannot decide whether a new health concern has the same explanation as the recorded condition.
  • Ask what specific clinical question an investigation is intended to address and how its result would affect the personal plan. A general reference discussing metabolic problems is not a finding that such problems are present or a compulsory laboratory panel. The retained ECG services do not establish a cardiac abnormality, and a facial-filler association is not a diagnostic test. The page does not select genetic testing, an ECG, imaging or a monitoring interval; those decisions need the responsible team's assessment and the person's actual history.
  • This leaf retains G0429, three routine ECG associations, Q2026 and Q2028 in their original order and article contexts. The ECG rows distinguish tracing, interpretation/report and the combined service; they are not findings or a compulsory workup. G0429's facial/antiretroviral example does not establish facial involvement or treatment exposure in an individual. Q2026 describes RADIESSE in a 0.1 ML billing unit, and Q2028 describes SCULPTRA in a 0.5 MG unit. Those literal units are not administered doses, a product choice or proof of eligibility or current coverage.
  • When reviewing an existing report or proposed assessment, ask what was actually observed, what question remains open and who will explain the result. A code title, inclusion example or service description is not the result of that assessment. Missing information is not automatically a normal finding, and the absence of a particular related link does not establish that an investigation is unnecessary. The page cannot provide a diagnostic checklist for every subtype or a universal schedule; the clinical reason and documented context should remain visible.
Common management context
  • The NIH source advises people with HIV-associated concerns to discuss options with their healthcare provider and not stop HIV medicines without consultation. This page does not choose an antiretroviral substitution or direct a change in an existing regimen. The fact that a source mentions selected procedures or other medicines does not establish suitability for a reader. Ask what a proposed measure is intended to address and how risks, alternatives and the underlying clinical context will be assessed. No injectable filler, product, dose, diet or activity programme is prescribed here.
  • Clarify which team will explain the recorded changes, review actual results and coordinate any discussion involving HIV medicines. Keep the prescribed regimen and the team's existing instructions separate from a general source's list of options. The code does not predict the course of fat changes, establish that a medicine must be replaced or promise a response to a procedure. Follow-up should reflect the personal clinical plan rather than a schedule inferred from a billing article, classification note or historical reference.
  • An educational code page cannot determine the cause or urgency of a new health concern. Discuss a changing concern with the responsible clinical team and use the personal safety instructions they have provided; do not wait for a code or terminology question to be settled if medical attention is needed. This explanation does not replace assessment, establish that a symptom is harmless or supply a home rule for excluding another problem. Existing prescribed medicines and any changes to them require the appropriate treating team.
  • A useful shared discussion separates the documented problem, the goal of a proposed measure, the evidence applicable to that person and the arrangements for review. Ask which uncertainties remain and what alternatives need consideration. Neither an entry in this classification branch nor a historical research result selects a medicine, a dose, a dietary target, a genetic test, a cosmetic injection or an operation. No service association guarantees access, reimbursement or benefit, and no general reference promises a particular recovery or treatment response.

šŸ”Key distinctions

Important notes
  • The subtype distinctions do not establish a cause, gene, affected region, severity or an individual result. Partial and generalized contexts include both inherited and acquired examples; localized injection examples do not establish exposure. The grouping parent remains unchanged.
  • HIV-associated coding retains its code-first note and conditional adverse-effect wording. Those notes do not establish a drug cause, and a displayed incomplete stem is not a final encounter code. Parent notes and clinical-source terminology do not become extra diagnoses or silent repairs.
  • Qualified ECG and facial-filler associations remain billing context, not a prescribed workup, procedure performed, product indication, administered dose, eligibility or present coverage. Relevant references are selected separately for each leaf; no shared treatment pathway is assigned.
  • The exact stored Index route is Lipodystrophy > HIV-associated. It retains its original wording and does not identify an adverse-effect culprit, body region or specific treatment. The other lipodystrophy entries remain distinct classification alternatives. Neither a parent-level genetic map nor a facial-filler billing description changes this exact route, supplies a medicine history or authorizes new coding details. The original inclusion and exclusion arrays remain empty at this leaf.
  • The selected NIH HIVinfo fact sheet was reviewed in October 2024. It is patient education, not a newly reviewed comprehensive HIV-treatment guideline or an individual prescribing opinion. The selected CMS conventions are historical FY2026 material; the leaf's literal HIV and adverse-effect notes are separately checked against the pinned classification. Those source dates do not upgrade stored metadata, establish current product coverage or replace the responsible team's interpretation of the actual record.
  • All original notes, exclusions, inclusion terms, Index arrays, hierarchy, synonyms, URLs, source metadata, priorities, review flags, specialists, overrides, semantic caches and qualified service relationships remain available in their original places. This educational addition removes none of them and does not silently repair terminology, relationships or coding data. Reference selection is specific to the leaf: inherited, acquired, injection-related and HIV-associated examples are not presented as one common disease mechanism or treatment pathway. This is not individual clinical signoff or a current payment decision.
Related codes to consider
E88.10Lipodystrophy, unspecified
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.11Partial lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.12Generalized lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.
E88.13Localized lipodystrophy
Existing lipodystrophy siblings retain classification context, not interchangeable causes, new diagnoses, hereditary findings, investigation orders or treatment eligibility.

Code hierarchy

chapter
4Endocrine, nutritional and metabolic diseases (E00-E89)
block
E70-E88Metabolic disorders
category
E88Other and unspecified metabolic disorders
category
E88.1Lipodystrophy, not elsewhere classified
currentE88.1

Official coding notes

Applicable to
  • code for adverse effect, if applicable, to identify drug (T37.5X5-)
  • any human immunodeficiency virus [HIV] disease (B20)
Code first
  • any human immunodeficiency virus [HIV] disease (B20)
Use additional code
  • code for adverse effect, if applicable, to identify drug (T37.5X5-)

Where you may see this code

You may see this code in hospital records, discharge summaries, insurance claims, encounter documentation, referrals, or other healthcare billing and coding records.

Related specialists

EndocrinologistGeneral Physician

Coding guidelines

Common synonyms

HIV-associated lipodystrophy

Frequently asked questions

Code details

CodeE88.14
SystemICD10
Display nameHIV-associated lipodystrophy
ChapterEndocrine, nutritional and metabolic diseases (E00-E89)
BlockMetabolic disorders

Flags

BillableYes
Valid clinical useYes

Source

SourceICD-10
Version2026-annual
Releaseannual
Year2026

Index terms

Matched terms
Lipodystrophy

About this content

This page is prepared by HealthAssure's clinical team using official coding standards from ICD-10. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.